1 3 glucan / krebs

Radiolabeled glucans which bind to leukocytes, sites of infection, inflammation, atherosclerosis, or cancer

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,

Treatment of tumors with glucan compositions in mice and rats

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BRIEF SUMMARY OF THE INVENTION The present invention relates to a method for treating malignant tumors in mice and rats, and to a composition comprising a glucan in the form of an aqueous solution, and a composition comprising a glucan and known antitumor and/or anticancer agents which is useful as

Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

TABLE OF CONTENTS 1. Field of the Invention 2. Background of the Invention 2.1. Immunobiological ctivity of Particulate Glucans 2.2. Adverse Side Effects of Particulate Glucans 2.3. Unsuccessful Attempts to Solubilize Particulate Glucans 3. Summary of the Invention 4. Brief Description of the

.beta.-glucan methods and compositions that affect the tumor microenvironment

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION This disclosure relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule C3 in

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION The present invention relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule

Cancer therapy using beta glucan and antibodies

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different

Cancer therapy using beta glucan and antibodies

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different

Radiolabeled glucans covalently linked to a radiolabel binding moiety

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,

Radiolabled glucans covalently linked to a radiometal binding moiety

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,

Radiolabeled glucans covalently linked to a radiolabel binding moiety

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,

Carboxymethylated derivatives of .beta.-1,3-glucan

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

This invention relates to a treatment of tumors and a new derivative of .beta.-1,3-glucan usable for the treatment. For years there have been searches for substances which, with parenteral or oral administration, will cause the inhibition of tumor growth and the prolongation of the survival time of

Composition and method for treating cancer and immunological disorders resulting in chronic conditions

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

FIELD OF THE INVENTION The present invention is directed to a composition for treating early stages of various forms of malignancies, particularly melanoma and lung cancer, in mammals. In more advanced stages of malignancies, such as those involving larger tumors and/or metastases, the composition

Soluble phosphorylated glucan

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

TABLE OF CONTENTS 1. Field of the Invention 2. Background of the Invention 2.1. Immunobiological Activity of Particulate Glucans 2.2. Adverse Side Effects of Particulate Glucans 2.3. Unsuccessful Attempts to Solubilize Particulate Glucans 3. Summary of the Invention 4. Brief Description of the

Soluble phosphorylated glucan

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

TABLE OF CONTENTS 1. Field of the Invention 2. Background of the Invention 2.1. Immunobiological Activity of Particulate Glucans 2.2. Adverse Side Effects of Particulate Glucans 2.3. Unsuccessful Attempts to Solubilize Particulate Glucans 3. Summary of the Invention 4. Brief Description of the

Therapy-enhancing glucan

Nur registrierte Benutzer können Artikel übersetzen

Einloggen Anmelden

Throughout this application, various references are cited. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Beta-glucans have been

1 3 glucan/krebs

Radiolabeled glucans which bind to leukocytes, sites of infection, inflammation, atherosclerosis, or cancer

Treatment of tumors with glucan compositions in mice and rats

Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases

.beta.-glucan methods and compositions that affect the tumor microenvironment

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Cancer therapy using beta glucan and antibodies

Cancer therapy using beta glucan and antibodies

Radiolabeled glucans covalently linked to a radiolabel binding moiety

Radiolabled glucans covalently linked to a radiometal binding moiety

Radiolabeled glucans covalently linked to a radiolabel binding moiety

Carboxymethylated derivatives of .beta.-1,3-glucan

Composition and method for treating cancer and immunological disorders resulting in chronic conditions

Soluble phosphorylated glucan

Soluble phosphorylated glucan

Therapy-enhancing glucan

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird